CLERAD

CLERAD is a company specializing in the detection and management of ionizing radiation, primarily serving the medical sector with advanced detection devices designed to enhance surgical safety and precision. Founded in Clermont-Ferrand, France, CLERAD focuses on radiation detection technologies. The company has successfully completed 9 deals, with the most recent funding round occurring on August 5, 2019, where they raised EUR 262,500. CLERAD is not a subsidiary and has no known subsidiaries.

The company currently has a valuation of EUR 3. 132 mn. CLERAD specializes in the detection and management of ionizing radiation, particularly within the medical sector. The company's core product offerings include advanced devices such as the GAMMA-Sup Sentinel Lymph Node Probe, GAMMA-Am Monitoring Probe for isolated limb techniques, and the GAMMA-NODE Gamma Camera.

These products are designed to enhance the precision and safety of surgical procedures, especially in oncology, by facilitating the detection of radio-marked tissues and enabling radio-guided surgeries. Catering primarily to healthcare professionals, CLERAD serves hospitals, surgical centers, and specialized clinics across Europe, North America, and parts of Asia, adhering to stringent medical regulations and standards. CLERAD generates revenue through direct sales and service contracts for its range of radiation detection devices, primarily targeting healthcare facilities. The company offers various maintenance agreements that include preventive and corrective services to ensure optimal functioning of its equipment.

Transactions typically involve upfront payments for equipment purchases and ongoing fees for maintenance services, structured to support the longevity and reliability of the devices. The product line, including flagship offerings like the GAMMA-Sup and GAMMA-NODE, operates within a B2B framework, whereby healthcare providers engage directly with CLERAD for procurement and ongoing technical support. For future growth, CLERAD is focused on launching new products designed to further enhance radiation detection capabilities in surgical environments. The company is actively pursuing expansion into new geographic markets, particularly in Asia and North America, with plans to establish a presence by the end of 2023.

The funding raised in August 2019, totaling EUR 262,500, will be utilized to support product development and market entry initiatives.